ABOUT BAPA

Our Mission

Advocate – Educate – Communicate

We strive to organize Bangladeshi-American Pharmacists in a strong and professional platform so they can be more successful in their career and have a fulfilling experience in this country. We work to get the members involved in the socio-political process that determines their future. We hope to motivate everyone to contribute their time and talent to the betterment of the pharmacy profession here at home and in Bangladesh.

Specifically, the purpose of the organization is to foster cooperation and collaboration among Bangladeshi pharmacists residing in North America; to build and maintain relations with other pharmacists’ associations in North America, to support the profession of pharmacy in Bangladesh and in North America; to support and encourage the development of Pharmaceutical Science in Bangladesh; to develop and conduct programs for maintaining and improving the professional standards; to promote welfare of members’ families in case of need; to protect the professional interests of members of the Association.

Our Sponsors

Silver Sponsor

Silver Sponsor

Silver Sponsor

Pharmaceutical News

  • Diabetes drug as a possible treatment for prostate cancer
    on May 9, 2025 at 8:00 am

    An international team of scientists led by the Medical University of Vienna has identified similarities in the mechanisms of diabetes and cancer: as the researchers show, the protein PPARγ, which is central to the regulation of metabolic processes, can also influence the growth of prostate cancer cells. PPARγ is already known to be a target of certain drugs used to treat type 2 diabetes.

  • Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years
    on May 8, 2025 at 8:00 am

    Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it will invest USD 50 billion into the United States of America in the next five years. These investments further strengthen Roche's already significant US footprint with 13 manufacturing and 15 R&D sites across the Pharmaceutical and Diagnostics Divisions, and are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities.

  • Discovery explains Long COVID breathing problems
    on May 7, 2025 at 8:00 am

    Groundbreaking research from the University of Virginia School of Medicine has revealed crucial new insights into the immune systems of COVID-19 survivors, particularly those struggling with persistent breathing issues. The study shows that these patients have distinct changes in their immune system that link to the severity of their lung damage. This discovery holds promise for developing targeted treatments for the lung complications of Long COVID.

  • Harnessing generative AI to expand the mitochondrial targeting toolkit
    on May 6, 2025 at 8:00 am

    The mitochondrion, often referred to as the powerhouse of the cell, plays critical roles in cellular function, making it a prime organelle to target for fundamental studies, metabolic engineering, and disease therapies. With only a limited number of existing mitochondrial targeting sequences, a new study from the Carl R. Woese Institute for Genomic Biology demonstrates the utility of generative artificial intelligence for designing new ones.

  • Shingles vaccine lowers the risk of heart disease for up to eight years
    on May 5, 2025 at 8:00 am

    People who are given a vaccine for shingles have a 23% lower risk of cardiovascular events, including stroke, heart failure, and coronary heart disease, according to a study of more than a million people published in the European Heart Journal. The protective effect of the vaccine lasts for up to eight years and is particularly pronounced for men, people under the age of 60 and those with unhealthy lifestyles, such as smoking, drinking alcohol and being inactive.